{'fraction_non_alphanumeric': 0.013856812933025405, 'fraction_numerical': 0.0, 'mean_word_length': 5.518796992481203, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Current state of percutaneous transcatheter mitral valve therapies.

Mitral valve regurgitation (MR) is a frequent condition usually associated with heart failure and reduced survival. Surgery remains the gold standard treatment but a significant number of patients are not optimal candidates due to age, comorbidities or poor left ventricular function. In this subgroup of patients transcatheter mitral interventions have emerged as an alternative to offer improvement of symptoms and increase survival. MitraClip ® is the device with the largest clinical experience and it has been demonstrated to provide clinical benefit in selected patients. However, mitral apparatus is a complex scenario and there are several potential targets for improving mitral regurgitation. The aim of this paper was to review the current trnascatheter technology developed to treat MR.